Publication details

Výsledky terapie metastatického renálního karcinomu lékem everolimus – analýza údajů z klinického registru RENIS

Title in English Metastatic Renal Cell Carcinoma Treated with Everolimus – Data from the RENIS Clinical Registry
Authors

BÜCHLER Tomáš DUŠEK Ladislav FÍNEK Jindřich POPRACH Alexandr BUDŇÁKOVÁ Dita KANDRNAL Vít JARKOVSKÝ Jiří BORTLÍČEK Zbyněk KLIMEŠ Daniel ABRAHÁMOVÁ Jitka VYZULA Rostislav

Year of publication 2011
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords everolimus; renal cell carcinoma; therapy
Description Everolimus is an oral mTOR kinase inhibitor approved for the treatment of patients with metastatic renal cell carcinoma (mRCC) progressing during or after treatment with vascular endothelial growth factor (VEGF)-targeted agents. Using the national RENIS clinical registry, we have retrospectively analysed outcomes of patients treated for mRCC with everolimus. A total of 78 patients were evaluable. Median progression-free survival from the start of everolimus therapy was 7 months (95% confidence interval 2–12 months). Partial response or stable disease was achieved in 69% of patients. Treatment toxicity was predictable and serious adverse events occurred in only 6% of patients the most common being respiratory toxicity. Everolimus therapy provides significant clinical benefit for heavily pretreated mRCC patients after failure of VEGF-targeted therapy

You are running an old browser version. We recommend updating your browser to its latest version.

More info